Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk - PubMed (original) (raw)

Randomized Controlled Trial

Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk

Muthuvel Jayachandran et al. J Cardiovasc Transl Res. 2011 Dec.

Abstract

A woman's risk for metabolic syndrome (MS) increases at menopause, with an associated increase in risk for cardiovascular disease. We hypothesized that early menopause-related changes in platelet activity and concentrations of microvesicles derived from activated blood and vascular cells provide a mechanistic link to the early atherothrombotic process. Thus, platelet functions and cellular origin of blood-borne microvesicles in recently menopausal women (n = 118) enrolled in the Kronos Early Estrogen Prevention Study were correlated with components of MS and noninvasive measures of cardiovascular disease [carotid artery intima medial thickness (CIMT), coronary artery calcium (CAC) score, and endothelial reactive hyperemic index (RHI)]. Specific to individual components of the MS pentad, platelet number increased with increasing waist circumference, and platelet secretion of ATP and expression of P-selectin decreased with increasing blood glucose (p = 0.005) and blood pressure (p < 0.05), respectively. Waist circumference and systolic blood pressure were independently associated with monocyte- and endothelium-derived microvesicles (p < 0.05). Platelet-derived and total procoagulant phosphatidylserine-positive microvesicles, and systolic blood pressure correlated with CIMT (p < 0.05), but not with CAC or RHI. In summary, among recently menopausal women, specific platelet functions and concentrations of circulating activated cell membrane-derived procoagulant microvesicles change with individual components of MS. These cellular changes may explain in part how menopause contributes to MS and, eventually, to cardiovascular disease.

PubMed Disclaimer

Cited by

Plasma levels of E-selectin are associated with retinopathy in sickle cell disease.
Agouti I, Masson E, Loundou A, Jean E, Arnaud L, Abdili E, Berenger P, Lavoipierre V, Séguier J, Dignat-George F, Lacroix R, Bernit E. Agouti I, et al. Eur J Haematol. 2023 Mar;110(3):271-279. doi: 10.1111/ejh.13902. Epub 2022 Nov 30. Eur J Haematol. 2023. PMID: 36409296 Free PMC article.
Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement.
Salomon C, Das S, Erdbrügger U, Kalluri R, Kiang Lim S, Olefsky JM, Rice GE, Sahoo S, Andy Tao W, Vader P, Wang Q, Weaver AM. Salomon C, et al. Endocr Rev. 2022 May 12;43(3):441-468. doi: 10.1210/endrev/bnac009. Endocr Rev. 2022. PMID: 35552682 Free PMC article.
Peripheral Markers of Neurovascular Unit Integrity and Amyloid-β in the Brains of Menopausal Women.
Jayachandran M, Miller VM, Lahr BD, Bailey KR, Lowe VJ, Fields JA, Mielke MM, Kantarci K. Jayachandran M, et al. J Alzheimers Dis. 2021;80(1):397-405. doi: 10.3233/JAD-201410. J Alzheimers Dis. 2021. PMID: 33554914 Free PMC article.
Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study.
Jayachandran M, Lahr BD, Bailey KR, Miller VM, Kantarci K. Jayachandran M, et al. Menopause. 2020 Mar;27(3):305-310. doi: 10.1097/GME.0000000000001465. Menopause. 2020. PMID: 31934946 Free PMC article. Clinical Trial.
The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM. Miller VM, et al. Menopause. 2019 Sep;26(9):1071-1084. doi: 10.1097/GME.0000000000001326. Menopause. 2019. PMID: 31453973 Free PMC article. Review.

References

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. - DOI - PubMed
1. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136–147. doi: 10.1007/s00392-006-0351-5. - DOI - PubMed
1. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8:538–554. doi: 10.1111/j.1463-1326.2005.00545.x. - DOI - PubMed
1. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001). JAMA, 285, 2486–2497 - PubMed
1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480. doi: 10.1111/j.1464-5491.2006.01858.x. - DOI - PubMed

Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk - PubMed (original) (raw)